Hair Loss: Drugs That Cause It, Drugs That Treat It, and What the Evidence Says

What Causes Hair Loss?

Hair loss, medically termed alopecia, falls into several distinct categories, and the cause determines the treatment. Androgenetic alopecia (AGA) is the most common type, driven by dihydrotestosterone (DHT) sensitivity in genetically predisposed follicles. Other major categories include telogen effluvium (TE), alopecia areata (AA), traction alopecia, and scarring alopecias.

Androgenetic Alopecia

AGA follows predictable patterns, the Norwood scale in men and the Ludwig scale in women. DHT binds to androgen receptors in susceptible follicles, progressively shortening the anagen (growth) phase. A 2017 genome-wide association study published in PLOS Genetics identified more than 280 genetic loci associated with male-pattern baldness, confirming a strongly polygenic inheritance. [1]

Telogen Effluvium

Telogen effluvium is diffuse shedding triggered when a physical or emotional stressor pushes an abnormally large proportion of follicles into the resting (telogen) phase simultaneously. Common triggers include surgery, rapid weight loss, childbirth, fever, and, critically for telehealth patients, new medications. Shedding typically begins 2 to 4 months after the trigger and resolves once the underlying cause is corrected. [2]

Alopecia Areata

Alopecia areata is an autoimmune condition in which T-cells attack the hair follicle. It affects roughly 2% of the global population at some point in their lifetime. [3] Presentation ranges from a single coin-sized patch to complete scalp or body hair loss. JAK inhibitors have transformed treatment in this category over the past three years.

Scarring Alopecias and Less Common Types

Lichen planopilaris, discoid lupus, and central centrifugal cicatricial alopecia destroy the follicle permanently. Traction alopecia results from chronic mechanical tension. These require dermatology referral and are beyond the scope of drug-based telehealth management.

Drugs That Cause Hair Loss

Drug-induced alopecia is underreported and underrecognized. Most drug-related shedding is a form of telogen effluvium, though some agents cause anagen effluvium (rapid shedding of actively growing hairs, as seen with chemotherapy). [4]

Chemotherapy Agents

Cytotoxic drugs, cyclophosphamide, doxorubicin, taxanes, induce anagen effluvium in the majority of patients. Hair loss usually begins within 2 weeks of the first cycle and is almost always reversible. Scalp cooling (hypothermia caps) reduces chemotherapy-induced alopecia incidence by roughly 50% in some breast cancer regimens, based on a 2017 NEJM trial (N=182). [5]

Anticoagulants and Antithrombotics

Heparin and warfarin are among the longest-documented drug causes of TE. The newer direct oral anticoagulants (rivaroxaban, apixaban) carry a lower but non-zero risk. A 2019 review in the British Journal of Dermatology confirmed that alopecia is reported in post-marketing surveillance for all oral anticoagulant classes. [6]

Retinoids

Acitretin, isotretinoin, and high-dose vitamin A supplementation all produce diffuse TE. The risk with isotretinoin is dose-dependent; a 2021 cohort study found that patients taking cumulative doses above 120 mg/kg had a statistically higher rate of hair thinning than those at lower cumulative doses (P<0.01). [7]

Beta-Blockers and Antihypertensives

Propranolol and metoprolol both appear on pharmacovigilance databases as TE triggers. The mechanism is not fully established but may involve direct follicular vasoconstriction. ACE inhibitors (captopril, enalapril) are also implicated.

Antithyroid Drugs and Thyroid Hormones

Both hypothyroidism and hyperthyroidism cause diffuse hair loss independently. Paradoxically, carbimazole and propylthiouracil can also trigger TE during treatment. Levothyroxine, when over- or under-dosed, may perpetuate loss; TSH should be maintained in the lower half of the normal range (approximately 0.5 to 2.0 mIU/L) when treating thyroid-related alopecia. [8]

Mood Stabilizers and Antipsychotics

Lithium causes diffuse TE in an estimated 12 to 19% of patients. Valproate produces dose-dependent hair thinning and curling. Some atypical antipsychotics (quetiapine, olanzapine) carry lower but documented alopecia risk.

Hormonal Contraceptives

Progestin-dominant oral contraceptives with high androgenic activity (levonorgestrel, norethindrone) can accelerate AGA in genetically susceptible women. Switching to a pill with anti-androgenic progestin (drospirenone, cyproterone acetate) may slow progression. [9]

GLP-1 Receptor Agonists

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) list alopecia as an adverse event in their prescribing information. In the SURMOUNT-1 trial (N=2,539), tirzepatide-treated participants reported hair loss at rates between 5.7% and 6.9% depending on dose, versus 1.0% for placebo. [10] The mechanism is almost certainly rapid-weight-loss-induced TE rather than a direct follicular drug effect. Adequate protein intake (at least 1.2 g/kg lean body mass per day) and micronutrient repletion may reduce the severity.

The HealthRX clinical team uses the following triage framework for GLP-1-associated hair loss: confirm telogen effluvium pattern (diffuse, pull-test positive), check ferritin (target >70 ng/mL), zinc, and protein intake, then reassure the patient that shedding typically peaks at months 3 to 4 and resolves by month 6 without dose reduction in most cases.

Drugs That Treat Hair Loss

Minoxidil (Topical and Oral)

Minoxidil is an ATP-sensitive potassium channel opener that prolongs the anagen phase and increases follicle size. Topical minoxidil 5% foam was FDA-approved for men in 2006 (the 2% solution for men in 1991 and for women in 1992). A 2022 randomized trial in the Journal of the American Academy of Dermatology (N=90) found that oral minoxidil 1 mg daily produced non-inferior hair-count increases compared with topical 5% minoxidil in women with AGA at 24 weeks. [11]

Oral minoxidil dosing:

• Women: 0.25 to 1.25 mg daily
• Men: 1.25 to 5 mg daily (off-label; monitor for fluid retention and hypertrichosis)

Patients should expect 3 to 6 months before visible density changes. Shedding in the first 4 to 8 weeks of treatment is common and represents follicular synchronization, not worsening.

Finasteride (Oral and Topical)

Finasteride inhibits 5-alpha reductase type II, reducing scalp DHT by approximately 60 to 70%. The landmark placebo-controlled trial published in the Journal of the American Academy of Dermatology (N=1,553 men, 2 years) showed that finasteride 1 mg daily increased hair count by a mean of 107 hairs per 1 cm² target area versus a loss of 75 hairs in the placebo group. [12]

Topical finasteride 0.25% solution (applied once daily) has emerged as a lower-systemic-exposure option. A 2021 trial in JAMA Dermatology (N=84) demonstrated non-inferiority to oral finasteride on hair weight index at 52 weeks, with significantly lower serum DHT suppression (25% vs. 66%), which may reduce sexual side-effect risk. [13]

Finasteride is not FDA-approved for women and is contraindicated in pregnancy. Post-finasteride syndrome, persistent sexual and neuropsychiatric side effects after discontinuation, is the subject of ongoing investigation; the FDA added a label update in 2022 acknowledging this concern. [14]

Dutasteride

Dutasteride inhibits both type I and type II 5-alpha reductase, reducing serum DHT by up to 90%. It is approved for AGA in Japan and South Korea but remains off-label in the United States for hair loss. A 2019 Cochrane review found dutasteride 0.5 mg superior to finasteride 1 mg on hair count at 24 weeks, though long-term comparative data are limited. [15]

JAK Inhibitors for Alopecia Areata

The FDA approved baricitinib (Olumiant) 2 mg and 4 mg in June 2022 for adults with severe alopecia areata, making it the first systemic drug approved specifically for this indication. In the BRAVE-AA1 trial (N=654), 38.8% of patients on baricitinib 4 mg achieved a SALT (Severity of Alopecia Tool) score of 20 or below at week 36, versus 6.2% on placebo (P<0.001). [16]

Ritlecitinib (Litfulo) 50 mg was FDA-approved in June 2023 for severe AA in patients aged 12 and older. The ALLEGRO trial (N=718) showed 23% of ritlecitinib-treated patients achieved SALT score <20 at week 24 versus 1.6% for placebo. [17]

Ruxolitinib topical (Opzelura) cream 1.5% received FDA approval in July 2022 for non-scarring alopecia, though its trial data in AA specifically are more modest than those for the oral JAK inhibitors.

Spironolactone (Women Only)

Spironolactone is an aldosterone antagonist with anti-androgenic properties. At doses of 100 to 200 mg daily, it blocks androgen receptors in scalp follicles. No large randomized controlled trial has confirmed efficacy by objective hair-count methods, though a 2015 retrospective study (N=100) in the International Journal of Dermatology reported subjective improvement in 74% of women with AGA or hyperandrogenic alopecia after 12 months. [18]

Spironolactone requires contraception in women of reproductive age due to teratogenicity risk and can cause menstrual irregularity, particularly at doses above 100 mg.

Low-Level Laser Therapy (LLLT)

LLLT devices, including FDA-cleared combs (HairMax LaserComb) and helmets, deliver red light at 650 to 900 nm wavelengths to scalp follicles. The mechanism likely involves photobiomodulation of mitochondrial cytochrome c oxidase in follicular cells. A 2014 randomized sham-controlled trial (N=128) in the American Journal of Clinical Dermatology found a 39% increase in hair density in the treatment group after 26 weeks. [19]

Platelet-Rich Plasma (PRP)

PRP involves concentrating autologous growth factors (PDGF, VEGF, IGF-1) from centrifuged blood and injecting them into the scalp. A 2019 meta-analysis in Dermatologic Surgery (9 RCTs, N=234) found statistically significant improvements in hair density and hair diameter with PRP versus placebo injection (P<0.05), though study heterogeneity was high. [20]

Ketoconazole Shampoo

Ketoconazole 2% shampoo has modest evidence as an adjunct for AGA. It reduces scalp Malassezia colonization and may have weak anti-androgenic effects at the follicular level. A 1998 controlled trial found it comparable to 2% minoxidil lotion on hair-density improvement over 6 months, though this finding has not been replicated in large trials. [21]

How Hair Loss Is Diagnosed

Clinical History and Drug Review

A thorough medication reconciliation is mandatory. Ask about supplements (high-dose vitamin A, biotin above 10 mg/day), hormonal therapies, and recently started or stopped medications. The timing of hair loss relative to drug changes typically follows a 2 to 4 month lag for TE. [2]

Physical Examination and Pull Test

A positive pull test, more than 6 hairs extracted from a single gentle pull on 40 to 60 hairs, indicates active shedding. Dermoscopy (trichoscopy) allows visualization of miniaturized follicles, yellow dots (AA), and perifollicular scale.

Laboratory Workup

A standard panel for diffuse hair loss includes TSH, free T4, serum ferritin (target >70 ng/mL for hair regrowth), complete blood count, comprehensive metabolic panel, zinc, DHEA-S, and total and free testosterone. Prolactin and ANA are added when clinical features suggest pituitary or connective tissue disease. [8]

The American Academy of Dermatology guideline on female-pattern hair loss (2021) states: "Serum ferritin below 30 ng/mL should be treated regardless of hemoglobin level in women presenting with diffuse hair loss." [22]

Scalp Biopsy

Biopsy with horizontal sectioning is the gold standard for distinguishing scarring from non-scarring alopecia and for confirming AA when trichoscopy is equivocal. Two 4 mm punch biopsies from the affected area are standard practice.

When to Worry About Hair Loss

Most hair shedding is benign and reversible. Seek prompt evaluation for any of the following:

• Scalp pain, burning, or pruritus alongside hair loss (possible scarring alopecia or inflammatory condition)
• Associated systemic symptoms such as fatigue, cold intolerance, weight changes, or joint pain (possible thyroid, iron-deficiency anemia, or lupus)
• Rapid onset of patchy loss in circles or bands (alopecia areata or tinea capitis)
• Loss at the frontal hairline in women with signs of hyperandrogenism (possible polycystic ovary syndrome)
• Hair loss in a child under 12 years old

A 2020 analysis in JAMA Dermatology noted that a 6-month delay between symptom onset and dermatology referral was associated with significantly worse treatment outcomes in scarring alopecias, where follicle destruction is irreversible. [23]

Special Populations

Post-Bariatric and Rapid-Weight-Loss Patients

TE is extremely common after bariatric surgery, affecting 40 to 75% of patients within 3 to 6 months post-operatively. Protein, zinc, iron, and biotin deficiencies all contribute. Pre-operative optimization of nutritional status and post-operative supplementation with a high-protein diet (>60 g/day minimum) and a bariatric-formulated multivitamin reduces but does not eliminate risk. [24]

Postpartum Alopecia

Up to 50% of postpartum women experience TE peaking at 3 to 5 months after delivery. The condition is self-limiting in the vast majority of cases, resolving by 12 months. No pharmacological intervention has demonstrated benefit in controlled trials for postpartum TE specifically; reassurance and iron/ferritin repletion remain standard of care.

Transgender and Gender-Diverse Patients on Hormone Therapy

Testosterone therapy in transmasculine patients can trigger or accelerate AGA. Finasteride 1 mg daily may be added after 6 months of stable testosterone dosing if AGA progresses. In transfeminine patients, estradiol and anti-androgens (spironolactone, cyproterone acetate) generally arrest or partially reverse AGA, though results vary by duration of prior androgen exposure. [25]